Skip to main content
SpringerLink
Log in

A public-private partnership to unlock the untargeted kinome

  • Commentary
  • Published:

From Nature Chemical Biology

View current issue Submit your manuscript

Chemical probes are urgently needed to functionally annotate hitherto-untargeted kinases and stimulate new drug discovery efforts to address unmet medical needs. The size of the human kinome combined with the high cost associated with probe generation severely limits access to new probes. We propose a large-scale public-private partnership as a new approach that offers economies of scale, minimized redundancy and sharing of risk and cost.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Value chain of kinase inhibitors based on validation for biological investigations.

References

  1. Fedorov, O., Muller, S. & Knapp, S. Nat. Chem. Biol. 6, 166–169 (2010).

    Article  CAS  Google Scholar 

  2. Edwards, A.M. et al. Nature 470, 163–165 (2011).

    Article  CAS  Google Scholar 

  3. Bantscheff, M. et al. Nat. Biotechnol. 25, 1035–1044 (2007).

    Article  CAS  Google Scholar 

  4. Patricelli, M.P. et al. Chem. Biol. 18, 699–710 (2011).

    Article  CAS  Google Scholar 

  5. Davis, M.I. et al. Nat. Biotechnol. 29, 1046–1051 (2011).

    Article  CAS  Google Scholar 

  6. Lin, X. et al. J. Med. Chem. 55, 5749–5759 (2012).

    Article  CAS  Google Scholar 

  7. Fedorov, O. et al. Proc. Natl. Acad. Sci. USA 104, 20523–20528 (2007).

    Google Scholar 

  8. Frye, S.V. Nat. Chem. Biol. 6, 159–161 (2010).

    Article  CAS  Google Scholar 

  9. Workman, P. & Collins, I. Chem. Biol. 17, 561–577 (2010).

    Article  CAS  Google Scholar 

  10. Weigelt, J. EMBO Rep. 10, 941–945 (2009).

    Article  CAS  Google Scholar 

  11. Cohen, P. Biochem. J. 425, 53–54 (2010).

    Article  CAS  Google Scholar 

  12. Dowling, J.E. et al. ACS Med. Chem. Lett. 3, 278–283 (2012).

    Article  CAS  Google Scholar 

  13. Al-Lazikani, B., Banerji, U. & Workman, P. Nat. Biotechnol. 30, 679–692 (2012).

    Article  CAS  Google Scholar 

  14. Di Paolo, J.A. et al. Nat. Chem. Biol. 7, 41–50 (2011).

    Article  CAS  Google Scholar 

  15. Deng, X. et al. Nat. Chem. Biol. 7, 203–205 (2011).

    Article  CAS  Google Scholar 

  16. Medina, J.R. et al. J. Med. Chem. 54, 1871–1895 (2011).

    Article  CAS  Google Scholar 

  17. Zhang, T. et al. Chem. Biol. 19, 140–154 (2012).

    Article  CAS  Google Scholar 

  18. Zhang, J. et al. Natur. 463, 501–506 (2010).

    Article  CAS  Google Scholar 

  19. Fedorov, O. et al. Chem. Biol. 18, 67–76 (2011).

    Article  CAS  Google Scholar 

  20. Mott, B.T. et al. Bioorg. Med. Chem. Lett. 19, 6700–6705 (2009).

    Article  CAS  Google Scholar 

  21. Shimomura, T. et al. Mol. Cancer Ther. 9, 157–166 (2010).

    Article  CAS  Google Scholar 

  22. Koeberle, S.C. et al. Nat. Chem. Biol. 8, 141–143 (2011).

    Article  Google Scholar 

  23. Bergamini, G. et al. Nat. Chem. Biol. 8, 576–582 (2012); corrigendum 8, 737 (2012).

    Article  CAS  Google Scholar 

  24. Golding, S.E. et al. Mol. Cancer Ther. 8, 2894–2902 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Stefan Knapp is in the Department of Clinical Pharmacology, and the Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK, Structural Genomics Consortium, University of Oxford, Oxford, UK.,

    Stefan Knapp

  2. Paulo Arruda and Paulo Mazzafera are in the Institute of Biology at the State University of Campinas, Campinas, Brazil.,

    Paulo Arruda & Paulo Mazzafera

  3. Division of Cancer Therapeutics, Julian Blagg and Paul Workman are in the Cancer Research UK Cancer Therapeutics Unit, the Institute of Cancer Research, London, UK.,

    Julian Blagg & Paul Workman

  4. Stephen Burley is in the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California–San Diego, San Diego, California, USA.,

    Stephen Burley

  5. Aled Edwards is at the Structural Genomics Consortium, Toronto, Ontario, Canada.,

    Aled Edwards

  6. Doriano Fabbro is with the Expertise Platform Kinases, Novartis, Basel, Switzerland.,

    Doriano Fabbro

  7. Nathanael S. Gray is at the Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.,

    Nathanael S Gray

  8. Bernhard Kuster is at Technische Universität München, München, Germany.,

    Bernhard Kuster

  9. Karen E. Lackey and Paul Gillespie are at Pharmaceutical Research and Early Development, Hoffmann–La Roche, Nutley, New Jersey, USA.,

    Paul Gillespie & Karen E Lackey

  10. Nicholas C.O. Tomkinson is at the University of Strathclyde, Glasgow, UK.,

    Nicholas C O Tomkinson

  11. Timothy M. Willson and William J. Zuercher are in the Department of Chemical Biology at GlaxoSmithKline, David H. Drewry, Research Triangle Park, North Carolina, USA.,

    David H Drewry, Timothy M Willson & William J Zuercher

Authors
  1. Stefan Knapp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paulo Arruda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Julian Blagg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephen Burley
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David H Drewry
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aled Edwards
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Doriano Fabbro
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Paul Gillespie
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nathanael S Gray
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Bernhard Kuster
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Karen E Lackey
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Paulo Mazzafera
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Nicholas C O Tomkinson
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Timothy M Willson
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Paul Workman
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. William J Zuercher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William J Zuercher.

Ethics declarations

Competing interests

S.K. and A.E. are in the Structural Genomics Consortium, an organization that is funded in part to generate research tools and place them in the public domain without restriction on use. J.B. and P.W. are employees of the Institute of Cancer Research, which has a commercial interest in inhibitors of several kinases. P.W. has relevant commercial interactions with Piramed Pharma, Genentech, Chroma Therapeutics, Sareum, Cyclacel, Astex Pharmaceuticals and AstraZeneca.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knapp, S., Arruda, P., Blagg, J. et al. A public-private partnership to unlock the untargeted kinome. Nat Chem Biol 9, 3–6 (2013). https://doi.org/10.1038/nchembio.1113

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nchembio.1113

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation